Immunological properties of plaque purified strains of live attenuated respiratory syncytial virus (RSV) for human vaccine

Vaccine

Volumn 17, Issue 2, 1999, Pages 172-181

  Herlocher, M L ^a   Ewasyshyn, M ^b   Sambhara, S ^b   Gharaee Kermani, M ^a   Cho, D ^a   Lai, J ^a   Klein, M ^b   Maassab, H F ^a  

^a U   (United States)

^b Pasteur Merieux Connaught Canada   (Canada)

Author keywords

BALB c mice; Immunogenicity; Live vaccine; Respiratory synctyal virus

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; LIVE VACCINE; NEUTRALIZING ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANTIBODY TITER; ARTICLE; BRONCHIOLITIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; INTRANASAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TEMPERATURE SENSITIVITY; VACCINATION; VIRUS ATTENUATION; VIRUS CULTURE; VIRUS MUTANT; VIRUS PNEUMONIA;

AGED; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MICE; MICE, INBRED BALB C; MUTATION; NEUTRALIZATION TESTS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; T-LYMPHOCYTES, CYTOTOXIC; TEMPERATURE; VACCINES, ATTENUATED; VIRAL VACCINES; VIRUS CULTIVATION;

EID: 0032889975     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00155-8     Document Type: Article

References (45)

1. Chanock R.M., Parrott R.H. Acute respiratory disease in infancy and childhood: present understanding and prospects for prevention. Pediatrics. 36:1965;21-39.
2. Brandt C.D., Kim H.W., Arrobio J.O.et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C. III. Composite analysis of eleven consecutive yearly epidemics. Am. J. Epidemiol. 98:1973;355-364.
3. Kim H.W., Arrobio J.O., Brandt C.D.et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am. J. Epidemiol. 98:1973;216-225.
4. McIntosh K, Chanock RM. Respiratory syncytial virus. In: Fields BN, Knipe DM. (Eds.), Virology, 2nd ed. Raven Press, New York, 1990, pp. 1045-1072.
5. Hall C.B., McBride J.T. Respiratory syncytial virus - from chimps with colds to conundrums and cures. New Engl. J. Med. 325:1991;57-58.
6. Falsey A.R., Cunningham C.K., Barker W.H.et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis. 172:1995;389-394.
7. Warren K.S. New scientific opportunities and old obstacles in vaccine development. Proc. Natl. Acad. Sci. USA. 83:1986;9275-9277.
8. Walsh JA. Establishing Health Priorities in the Developing World. United Nations Development Programme, New York, 1988.
9. Murphy B.R., Hall S.L., Kulkarni A.B.et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 32:1994;13-36.
10. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89:1969;405-421.
11. Kim H.W., Canchola J.G., Brandt C.D.et al. Respiratory syncytial virus diseases in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:1969;422-433.
12. Chin J., Magoffin R.L., Shearer L.A., Schieble J.H., Lennette E.H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89:1969;449-463.
13. Kakuk T.J., Soike K., Brideaul R.J.et al. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J. Infect. Dis. 167:1993;553-561.
14. Piedra P.A., Wyde P.R., Castleman W.L.et al. Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon. Vaccine. 11:1993;1415-1423.
15. Graham B.S. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. Am. J. Respir. Crit. Care Med. 152:1995;S63-S66.
16. Gharpure M.A., Wright P.F., Chanock R.M. Temperature-sensitive mutants of respiratory syncytial virus. J. Virol. 3:1969;414-421.
17. Hodes D.S., Kim H.W., Parrott R.H., Camargo E., Chanock R.M. Genetic alteration in a temperature-sensitive mutant of respiratory syncytial virus after replication in vivo (37972). Proc. Soc. Exp. Biol. Med. 145:1974;1158-1164.
18. McIntosh K., Arbeter A.M., Stahl M.K., Orr I.A., Hodes D.S., Ellis E.F. Attenuated respiratory syncytial virus vaccines in asthmatic children. Pediatr. Res. 8:1974;689-696.
19. Wright P.F., Shinozaki T., Fleet W., Sell S.H., Thompson J., Karzon D.T. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J. Pediatr. 88:1976;931-936.
20. Wright P.F., Belshe R.B., Kim H.W., Van Voris L.P., Chanock R.M. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect. Immun. 37:1982;397-400.
21. Belshe R.B., Anderson E.L., Walsh E.E. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J. Infect. Dis. 168:1993;1024-1029.
22. Crowe J.E. Jr., Collins P.L., London W.T., Chanock R.M., Murphy B.R. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine. 11:1993;1395-1404.
23. Kim H.W., Arrobio J.O., Brant C.D.et al. Safety and antigenicity of temperature sensitive (ts) mutant respiratory syncytial virus (RSV) in infants and children. Pediatrics. 52:1973;56-63.
24. Forsyth BR, Phillips CA. Laboratory and antigenic studies of respiratory syncytial virus; evaluation of respiratory syncytial, meningococcal, and pneumococcal polysaccharide vaccines. NIH contract report number IDB-VDP-07-067, 1973.
25. Richardson L.S., Belshe R.B., Sly D.L.et al. Experimental respiratory syncytial virus pneumonia in cebus monkeys. J. Med. Virol. 2:1978;45-59.
26. Friedewald W.T., Forsyth B.R., Smith C.B., Gharpure M.S., Chanock R.M. Low-temperature grown RS virus in adult volunteers. J. Am. Med. Assoc. 204:1968;690-694.
27. Kim H.W., Arrobio J.O., Pyles G.et al. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus. Pediatrics. 48:1971;745-755.
28. Crowe J.E. Jr., Bui P.T., London W.T.et al. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine. 12:1994;691-699.
29. Crowe J.E. Jr., T Bui P., Davis A.R., Hung P.P., Chanock R.M., Murphy B.R. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus (RSVcpts-248) retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine. 12:1994;783-790.
30. Maassab H.F. Adaptation and growth characteristics of influenza virus at 25°C. Nature (London). 213:1967;612-614.
31. Maassab H.F., DeBorde D.C. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine. 3:1985;355-369.
32. Gharaee-Kermani M, Herlocher ML, Ewasyshyn M, Maassab HF. Evaluation of candidate strains of live-attenuated respiratory syncytial virus (RSV) for human vaccine. Arch. Virol., in press.
33. Graham B.S., Henderson G.S., Tang Y., Lu X., Neuzil K.M., Colley D.G. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immun. 151:1993;2032-2040.
34. Randolph V.B., Kandis M., Stemler-Higgins P.et al. Attenuated temperature-sensitive respiratory syncytial virus mutants generated by cold adaptation. Virus Res. 33:1994;241-259.
35. Fernie B.F., Ford E.C., Gerin J.L. The development of BALB/c cells persistently infected with respiratory syncytial virus: presence of ribonucleoprotein on the cell surface. Proceed. Soc. for Exp. Biol. and Med. 167:1981;83-86.
36. Walsh E.E., Schlesinger J.H.J., Brandriss M.W. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect. Immun. 43:1984;756-758.
37. Murphy B.R., Walsh E.E. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J. Clin. Microbiol. 26(8):1988;1595-1597.
38. Nicholas J.A., Rubino K.L., Levely M.E., Adams E.G., Collins P.L. Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins. J. Virol. 64:1990;4232-4241.
39. Waris M.E., Tsou C., Erdman D.D., Zake S.R., Anderson L.J. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70:1996;2852-2860.
40. Mosmann T.R., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today. 17:1996;138-146.
41. Rouse B.T., Norley S., Martin S. Antiviral cytotoxic T lymphocyte induction and vaccination. Reviews Infect. Dis. 19(1):1988;16-33.
42. Bangham C.R.M., Cannon M.J., Karzon D.T., Askonas B.A. Cytotoxic T-cell response to respiratory syncytial virus in mice. J. Virol. 56:1985;55-59.
43. Connors M., Kulkarni A.B., Firestone C.et al. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J. Virol. 66:1992;7444-7451.
44. Maassab HF, Heilman CA, Herlocher ML. Cold-adapted influenza viruses for use as live vaccines for man. In: Viral Vaccines. Wiley-Liss, New York, 1990, pp. 203-242.
45. Bakshi S.S., Cooper L.Z. Rubella and mumps vaccines. Pediatr. Clin. North Am. 37(3):1990;651-658.